Zobrazeno 1 - 10
of 181
pro vyhledávání: '"Aviral Singh"'
Autor:
Cristina Müller, Aviral Singh, Christoph A. Umbricht, Harshad R. Kulkarni, Karl Johnston, Martina Benešová, Stefan Senftleben, Dirk Müller, Christiaan Vermeulen, Roger Schibli, Ulli Köster, Nicholas P. van der Meulen, Richard P. Baum
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-10 (2019)
Abstract Background For almost a decade, terbium radioisotopes have been explored for their potential theragnostic application in nuclear medicine: 152Tb and 155Tb are the radioisotopes identified for PET or SPECT imaging, while 149Tb and 161Tb have
Externí odkaz:
https://doaj.org/article/7eda5b3c70fa41ca97364e47bb48a567
Autor:
Gangaram Choudhary, V.K. Jain, Lokesh Maan, Mahesh Kumar Mishra, Jitendra Kumar, Aviral Singh
Publikováno v:
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH. :51-53
Background: Tuberculosis (TB) is a disease most commonly affecting the lungs caused by mycobacterium tuberculosis, may also affect any parts of the body. Diabetes mellitus (DM) is recognized as a major risk factor for the progression of active pulmon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fee2d9c69cab20e5be74ec0bedf141c4
https://doi.org/10.36106/ijsr/3401809
https://doi.org/10.36106/ijsr/3401809
Autor:
Frankis Almaguel, Franz C Robiller, Aviral Singh, Dirk Mueller, Christiane Smerling, Maythinee Chantadisai, Aleksandr Eismant, Christiane Schuchardt, Jingjing Zhang, Frank Osterkamp, Aileen Hoehne, Dirk Zboralski, Ulrich Reineke, Richard P. Baum, Harshad R. Kulkarni
Publikováno v:
Journal of Nuclear Medicine. 63:415-423
Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides for theranostic applications. We present the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f35f8af36fef73ab6f39170d0ad64af2
https://doi.org/10.2967/jnumed.120.259192
https://doi.org/10.2967/jnumed.120.259192
Autor:
Aviral Singh, Nisaar Korowlay, Lucille Heslop, Masha Maharaj, Trisha Govender, Mike Sathekge, Partha Choudhary
Publikováno v:
Nucl Med Mol Imaging
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 ((177)Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer (mCRPC), and retrospective data have shown this therapy to be favourably
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::786e14c67f0cd2b73c26c2560d365e0d
https://doi.org/10.1007/s13139-021-00696-5
https://doi.org/10.1007/s13139-021-00696-5
Autor:
Tobias Rydén, Michael Pröhl, Dirk Müller, Harshad R. Kulkarni, Peter Bernhardt, Nicholas P. van der Meulen, Jan Rijn Zeevaart, Christiane Schuchardt, Richard P. Baum, Nadezda Gracheva, Pascal V. Grundler, Cristina Müller, Aviral Singh, Roger Schibli, Ulli Köster
Publikováno v:
J Nucl Med
(161)Tb has decay properties similar to those of (177)Lu but, additionally, emits a substantial number of conversion and Auger electrons. The aim of this study was to apply (161)Tb in a clinical setting and to investigate the feasibility of visualizi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4bf94b99d04091bc7f13a2d797833c1
https://doi.org/10.2967/jnumed.120.258376
https://doi.org/10.2967/jnumed.120.258376
Autor:
Peter Kletting, Christiane Schuchardt, Harshad R Kulkarni, Mostafa Shahinfar, Aviral Singh, Gerhard Glatting, Richard P Baum, Ambros J Beer
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0162303 (2016)
In molecular radiotherapy with 177Lu-labeled prostate specific membrane antigen (PSMA) peptides, kidney and/or salivary glands doses limit the activity which can be administered. The aim of this work was to investigate the effect of the ligand amount
Externí odkaz:
https://doaj.org/article/84cf762f2a6e41a3bd5c9d80d2f21c84
Autor:
Christiane Schuchardt, Richard P. Baum, Jingjing Zhang, Harshad R. Kulkarni, Aviral Singh, Qingxing Liu
Publikováno v:
Journal of Nuclear Medicine, 61(11), 1560-1569. Society of Nuclear Medicine and Molecular Imaging
The objective of this retrospective study was to determine the role of F-18-FDG PET/CT in a large cohort of 495 patients with metastatic neuroendocrine neoplasms (NENs) who were treated with peptide receptor radionuclide therapy (PRRT) with a long-te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2670b6ddddb999569999ce90128473ea
https://doi.org/10.2967/jnumed.119.241414
https://doi.org/10.2967/jnumed.119.241414
Autor:
Richard P. Baum, Eric P. Krenning, Mark Kidd, Giovanni Paganelli, Stefano Severi, Anna Malczewska, Irvin M. Modlin, Wouter A. van der Zwan, Ignat Drozdov, Dik J. Kwekkeboom, Aviral Singh, Lisa Bodei
Publikováno v:
Eur J Nucl Med Mol Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 47, 895-906. Springer-Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 47, 895-906. Springer-Verlag
PURPOSE: Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Q
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ca03451201c668e5911cd78a1a07151
https://doi.org/10.1007/s00259-019-04601-3
https://doi.org/10.1007/s00259-019-04601-3
Autor:
Ameya D. Puranik, MD, FEBNM, Harshad R. Kulkarni, MD, Aviral Singh, MD, Richard P. Baum, MD, PhD
Publikováno v:
AACE Clinical Case Reports, Vol 1, Iss 2, Pp e131-e135 (2015)
ABSTRACT: Objective: Peptide receptor radionuclide therapy (PRRT) with 90Yttrium (90Y)- and 177Lutetium (177Lu)-labeled somatostatin analogs are the accepted standard of care for treatment of metastatic well-differentiated neuroendocrine tumors (NET)
Externí odkaz:
https://doaj.org/article/8ce7ff27748d4ca48c4c10e548484b27
Autor:
Arthur Jochems, Dieter Hörsch, Karin Niepsch, Philippe Lambin, Merten Hommann, Daniel Kaemmerer, Franz C Robiller, Richard P. Baum, Vikas Prasad, Harshad R. Kulkarni, Aviral Singh, Holger Franz, Dirk Mueller
Publikováno v:
Oncotarget, 9(24), 16932-16950. Impact Journals LLC
Oncotarget
Oncotarget
// Richard P. Baum 1 , Harshad R. Kulkarni 1 , Aviral Singh 1 , Daniel Kaemmerer 2 , Dirk Mueller 1 , Vikas Prasad 3 , Merten Hommann 2 , Franz C. Robiller 4 , Karin Niepsch 1 , Holger Franz 5 , Arthur Jochems 6 , Philippe Lambin 6, 7 and Dieter Hors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ea4c15b45ed8aaf69bf419a3dfe989
https://doi.org/10.18632/oncotarget.24524
https://doi.org/10.18632/oncotarget.24524